Hologic (HOLX) Wins Appeal on Patent Validity for SenoRx Case; Invalid Ruling Reversed
Bloomberg reporting that Hologic (Nasdaq: HOLX) has won an appeal on patent validity in its SenoRx case.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercore ISI Upgrades Hologic (HOLX) to Buy
- Netflix (NFLX) Director Jay Hoag Scoops Up 600,000 Shares
- McKesson (MCK) Discloses Civil Investigative Demand
Create E-mail Alert Related CategoriesLitigation
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!